Home » Stocks » LRMR

Larimar Therapeutics, Inc. (LRMR)

Stock Price: $17.02 USD 0.23 (1.37%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
Market Cap 266.01M
Revenue (ttm) n/a
Net Income (ttm) -42.48M
Shares Out 11.88M
EPS (ttm) -3.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $17.02
Previous Close $16.79
Change ($) 0.23
Change (%) 1.37%
Day's Open 16.99
Day's Range 16.63 - 17.57
Day's Volume 64,543
52-Week Range 0.62 - 25.87


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 9 months ago

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology...

Benzinga - 1 year ago

Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the com...

GlobeNewsWire - 1 year ago

Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant n...

Benzinga - 1 year ago

Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.

Benzinga - 1 year ago

Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndr...

About LRMR

Larimar Therapeutics, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

Dr. Carole S. Ben-Maimon
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements